Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 13/20 | 0.41 |
| ▸ | JAK3 | P52333 | 13/20 | 0.41 |
| ▸ | JAK1 | P23458 | 11/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | EIF2AK4 | Q9P2K8 | 3/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2034673 | 0.85 | JAK2 (0.43) | JAK2JAK3JAK1ADORA2A | |
| SCHEMBL1996420 | 0.83 | JAK2 (0.47) | JAK2JAK3JAK1ADORA2APIK3CA | |
| SCHEMBL14852933 | 0.81 | JAK2 (0.46) | JAK2JAK3JAK1ADORA2APIK3CA | |
| SCHEMBL12644096 | 0.81 | JAK2 (0.43) | JAK2JAK3JAK1ADORA2APIK3CA | |
| SCHEMBL2035111 | 0.80 | JAK2 (0.42) | JAK2JAK3JAK1ADORA2APIK3CA | |
| SCHEMBL1991742 | 0.78 | JAK2 (0.45) | JAK2JAK3JAK1ADORA2APIK3CA | |
| SCHEMBL2031715 | 0.78 | JAK2 (0.40) | JAK2JAK3JAK1 | |
| SCHEMBL16824620 | 0.78 | JAK2 (0.43) | JAK2JAK3JAK1ADORA2APIK3CA | |
| SCHEMBL12067354 | 0.78 | JAK2 (0.44) | JAK2JAK3JAK1ADORA2APIK3CA | |
| SCHEMBL2032583 | 0.78 | JAK2 (0.44) | JAK2JAK3JAK1PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK3 3/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.